Real-world outcomes for peripheral T‑cell lymphoma in Chinese adults

A Multicenter, Non-interventional, Two-cohort Study to Describe Real-world Treatment Patterns and Outcomes in Patients With Peripheral T-cell Lymphoma

This project will collect past and new clinical and molecular data to see which treatments and biomarkers work best for adults in China with peripheral T‑cell lymphoma.

Quick facts

• Study type: Observational
• Enrollment: 3000 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Fudan University (other)
• Locations: 1 site (Shanghai, Shanghai Municipality)
• Trial ID: NCT07270861 on ClinicalTrials.gov

What this trial studies

This multicenter effort combines a retrospective cohort (patients treated 2010–2024) with a prospective cohort beginning October 2025 to build a large Chinese PTCL database. Investigators will describe treatment patterns, clinicopathologic features, and survival outcomes across participating centers. They will develop and validate prognostic models and compare real-world effectiveness and safety of different therapeutic strategies. Molecular analyses of tumors and relapse samples will be used to search for actionable targets and predictive biomarkers.

Who should consider this trial

Good fit: Adults (age ≥18) with a confirmed histopathologic diagnosis of peripheral T‑cell lymphoma who have available diagnostic and treatment records and were treated and followed at participating centers (retrospective: diagnosed 2010–2024; prospective: newly diagnosed from October 2025 onward).

Not a fit: Patients with NK/T‑cell lymphoma or primary cutaneous T‑cell lymphomas, those without a confirmed pathology report, or patients diagnosed elsewhere who did not receive primary treatment and follow‑up at a participating center are unlikely to benefit from this project.

Why it matters

Potential benefit: If successful, the project could help personalize therapy and improve outcomes by identifying better treatment approaches and biomarkers that predict response or relapse for Chinese patients with PTCL.

How similar studies have performed: Smaller cohort studies and clinical trials have identified some promising targeted agents and biomarkers in PTCL, but large multicenter real‑world databases in the Chinese population are limited, so this approach builds on prior signals while adding novel population‑scale data.

Eligibility criteria

Inclusion Criteria:

* Age ≥18 years, with a histopathologic diagnosis of PTCL (any subtype per WHO 2016 classification of hematolymphoid neoplasms).
* Cohort A: Patients diagnosed and treated at participating centers between 2010 and 2024.
* Cohort B: Patients newly diagnosed from October 2025 onward.
* Availability of basic diagnostic and treatment records .

Exclusion Criteria:

* Indeterminate diagnosis or missing pathology report.
* Patients diagnosed at an outside institution who did not receive their primary treatment and follow-up at a participating center.
* Diagnoses of NK/T-cell lymphoma or primary cutaneous T-cell lymphomas.

Where this trial is running

Shanghai, Shanghai Municipality

• Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China (RECRUITING)

Study contacts

• Study coordinator: Rong Tao, MD

Conditions: Peripheral T-Cell Lymphoma, T-cell lymphoma, Retrospective cohort, Prospective cohort, Epidemiology, Biomarkers